Core Viewpoint - JD Health's launch of a sleep center and internet sleep clinic aims to provide comprehensive, professional, and personalized sleep health solutions to millions suffering from sleep issues, integrating internet healthcare with health management [2][3]. Group 1: Market Demand and Context - Sleep issues are increasingly recognized as a significant health challenge, with nearly 25% of the population in China sleeping less than 6 hours and about 40% experiencing nighttime awakenings [2]. - The International Classification of Diseases (ICD-11) identifies over 90 types of sleep disorders, indicating a broad and urgent demand for diagnosis and treatment [2]. Group 2: Government Initiatives - The National Health Commission and the National Disease Control Bureau have mandated that by 2025, each city must have at least one hospital offering sleep clinic services, with similar requirements for districts in direct-controlled municipalities [3]. - The establishment of JD Health's sleep center aligns with national policies aimed at enhancing sleep disorder services [3]. Group 3: Service Offerings - JD Health's sleep center will utilize a combination of professional assessments and collaboration with top-tier hospital psychiatrists to provide comprehensive evaluations of users' sleep and psychological stress [3]. - The center will also feature an AI psychological companion, "Chatting with Yu Universe," available 24/7 to help alleviate user stress and promote healthy sleep [3]. Group 4: Product Availability - Users will have the option to purchase various sleep-related products, including medications, breathing machines, and melatonin, facilitating a one-stop shopping experience [4]. - The recent launch of the innovative drug Dazhuike® (generic name: Levorotary) on JD Health's platform represents a new treatment option for insomnia patients by precisely regulating sleep-wake rhythms [4]. Group 5: Future Plans - JD Health plans to deepen collaborations with medical institutions and experts to continuously improve service models and enhance user experience in sleep health services [4].

8月初，新型抗失眠药物莱博雷生（商品名：达卫可）在电商平台首发，第一天就售出8000多盒。谈及 这个数字，卫材中国总裁冯艳辉直呼"没想到"。 "原先我们只注意到医院市场。"就在莱博雷生上市前夕，一位院长还向她表达了对该产品的期待，因为 医院过去十多年都只有老药可用。 自2007年之后，国内失眠治疗领域一度长达十多年没有创新药上市，2023年上市的一款药物，虽然在作 用机制上有所创新，但仍属于传统的苯二氮类受体激动剂，同类药物使用历史已超过半个世纪。今年5 月底获批的莱博雷生，作为首个在中国上市的双食欲素受体拮抗剂，真正属于全新靶点的创新药，可谓 给国内失眠治疗带来一场革新。2024年，莱博雷生全球销售额为3.7亿美元，居同类产品之首。 今年28岁的李玮是北京一家小型创业公司的合伙人，三四年前进入所在行业，失眠史也差不多与此同 步。 冯艳辉总裁提到，虽然莱博雷生在已上市的20多个国家及地区均获得较好的市场反响，特别是在失眠大 国日本，莱博雷生在助眠药物处方市场的份额已达到40%。但在中国上市后的成绩仍出乎卫材团队的意 料之外，他们没想到在医院市场之外，莱博雷生的产品需求竟也如此旺盛。 因为属于非镇静类药物，对睡 ...

Core Insights - Eisai (China) Pharmaceutical Co., Ltd. has announced that its innovative drug, Lemborexant, has arrived in China and completed the drug inspection process, now being distributed to major hospitals and designated pharmacies nationwide, providing a new treatment option for insomnia patients [1][2] - Lemborexant can also be prescribed through the JD Health online platform, addressing the medication needs of insomnia sufferers [1] - The drug works by competitively binding to two orexin receptor subtypes (OX1R and OX2R), precisely regulating the orexin system to induce sleep without suppressing REM sleep, thus improving overall sleep structure [1][2] Product Approval and Market Position - Lemborexant was approved for sale in the United States in 2019 and has since received approval in over 20 countries and regions, including Japan, Canada, Australia, Hong Kong, and Macau [2] - In the U.S., it is indicated for adults with difficulties in falling asleep or maintaining sleep, while in Japan, it is a recommended treatment for insomnia as per the Japanese Consensus on Insomnia Disorder Treatment [2] - The drug received approval from the National Medical Products Administration (NMPA) in China in May 2025 for treating adult insomnia characterized by difficulty in falling asleep and/or maintaining sleep, and is included in the "Guidelines for the Diagnosis and Treatment of Adult Insomnia in China" [2] Strategic Focus - Eisai China positions the neuroscience field, including insomnia, as a key therapeutic area, aiming to provide innovative treatment options and management tools for insomnia patients [2] - The launch of Lemborexant is expected to reshape natural sleep rhythms and redefine sleep health management standards, contributing to the "Healthy China 2030" chronic disease prevention goals [2]